Delivery Order SPE2DB20D2104-SPE2DB25FMVXH
- Not listed
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $8,071.19 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed price, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $7,666.65 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with a completion date of July 30, 2025, and performance taking place at the contractor's Conshohocken, Pennsylvania location. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a $28,416.82 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award carries no set-aside designation, reflecting the company's proven capability to...
- The Defense Logistics Agency awarded a $11,410.74 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-set-aside contract represents a pediatric delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was made competitively and is...
- The Defense Logistics Agency awarded a $32,046.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 22, 2025, with completion targeted for July 23, 2025. This non-competitive, non-set-aside delivery order represents a child contract action under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement valued through December 2026. The product will...
- The Defense Logistics Agency awarded a $12,578.87 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion required by July 29, 2025. This is a firm fixed price, non-set-aside contract with performance location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $30,927.58 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $30,275.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be performed...
- The Defense Logistics Agency awarded a delivery order valued at $8,844.37 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMVXHDelivery Order
The Defense Logistics Agency awarded a $7,935.33 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside award represents a pediatric or adult rheumatoid arthritis treatment pharmaceutical, with performance occurring at the vendor's Conshohocken, Pennsylvania location. The delivery order functions as a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal military and veteran healthcare systems. This delivery order exemplifies the company's ongoing role in supplying brand-name and generic medications through the DLA's Medical Supply Chain to support Defense Health Agency and other federal healthcare programs. The award reflects the competitive procurement environment, with AmerisourceBergen's demonstrated capability to fulfill federal medical supply requirements across multiple therapeutic domains as the DLA Troop Support prepares to transition to Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards beginning in 2026.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 7/18/25 |